These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 10072106

  • 1. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.
    Harris GM, Stendt CL, Vollenhoven BJ, Gan TE, Tipping PG.
    Am J Hematol; 1999 Mar; 60(3):175-80. PubMed ID: 10072106
    [Abstract] [Full Text] [Related]

  • 2. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA, Bonnar J.
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [Abstract] [Full Text] [Related]

  • 3. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M, Kitchens CS, Khan FY.
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [Abstract] [Full Text] [Related]

  • 4. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.
    Quehenberger P, Kapiotis S, Pärtan C, Schneider B, Wenzel R, Gaiger A, Speiser W.
    Ann Hematol; 1993 Jul; 67(1):33-6. PubMed ID: 8392873
    [Abstract] [Full Text] [Related]

  • 5. Haemostatic changes and the oral contraceptive pill.
    Norris LA, Bonnar J.
    Baillieres Clin Obstet Gynaecol; 1997 Sep; 11(3):545-64. PubMed ID: 9488791
    [Abstract] [Full Text] [Related]

  • 6. Effect of low-dose oral triphasic contraceptives on blood viscosity, coagulation and lipid metabolism.
    Coata G, Ventura F, Lombardini R, Ciuffetti G, Cosmi EV, Di Renzo GC.
    Contraception; 1995 Sep; 52(3):151-7. PubMed ID: 7587186
    [Abstract] [Full Text] [Related]

  • 7. Coagulation studies in women using combination type of oral contraceptives.
    Sharma S, Sharma M, Soni IJ, Gupta A, Jain R.
    J Obstet Gynaecol India; 1983 Aug; 33(4):519-24. PubMed ID: 12339832
    [Abstract] [Full Text] [Related]

  • 8. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W.
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [Abstract] [Full Text] [Related]

  • 9. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR.
    Lancet; 1997 Jan 11; 349(9045):83-8. PubMed ID: 8996419
    [Abstract] [Full Text] [Related]

  • 10. Factor VII activation and oral contraceptives.
    Plu-Bureau G, Scarabin PY, Bara L, Malmejac A, Guize L, Samama M.
    Thromb Res; 1993 May 01; 70(3):275-80. PubMed ID: 8327993
    [Abstract] [Full Text] [Related]

  • 11. Contraceptive choices in women with coagulation disorders.
    Comp PC, Zacur HA.
    Am J Obstet Gynecol; 1993 Jun 01; 168(6 Pt 2):1990-3. PubMed ID: 8512043
    [Abstract] [Full Text] [Related]

  • 12. Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: relation to the development of cardiovascular disease.
    Kelleher CC.
    Am J Obstet Gynecol; 1990 Jul 01; 163(1 Pt 2):392-5. PubMed ID: 2196811
    [Abstract] [Full Text] [Related]

  • 13. Oral contraception and coagulation.
    Notelovitz M.
    Clin Obstet Gynecol; 1985 Mar 01; 28(1):73-83. PubMed ID: 3987135
    [Abstract] [Full Text] [Related]

  • 14. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP.
    Lancet; 1995 Dec 16; 346(8990):1593-6. PubMed ID: 7500751
    [Abstract] [Full Text] [Related]

  • 15. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY, Plu-Bureau G, Zitoun D, Bara L, Guize L, Samama MM.
    Thromb Haemost; 1995 Sep 16; 74(3):928-32. PubMed ID: 8571323
    [Abstract] [Full Text] [Related]

  • 16. An epidemiological study of the haemostatic and other effects of oral contraceptives.
    Meade TW, Brozović M, Chakrabarth R, Howarth DJ, North WR, Stirling Y.
    Br J Haematol; 1976 Nov 16; 34(3):353-64. PubMed ID: 990177
    [Abstract] [Full Text] [Related]

  • 17. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive.
    Cachrimanidou AC, Hellberg D, Nilsson S, von Schoulz B, Crona N, Siegbahn A.
    Contraception; 1994 Aug 16; 50(2):153-65. PubMed ID: 7956214
    [Abstract] [Full Text] [Related]

  • 18. Effects of oral contraceptives on blood coagulation. A review.
    Beller FK, Ebert C.
    Obstet Gynecol Surv; 1985 Jul 16; 40(7):425-36. PubMed ID: 3895067
    [Abstract] [Full Text] [Related]

  • 19. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G, Powell M, Marshall A, Woutersz TB, Steiner G.
    Int J Fertil Menopausal Stud; 1994 Jul 16; 39(5):283-91. PubMed ID: 7820162
    [Abstract] [Full Text] [Related]

  • 20. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
    Prasad RN, Koh SC, Viegas OA, Ratnam SS.
    Clin Appl Thromb Hemost; 1999 Jan 16; 5(1):60-70. PubMed ID: 10725985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.